Use of in vitro methods to predict QT prolongation

Toxicology and Applied Pharmacology

Volumn 207, Issue 2 SUPPL., 2005, Pages 446-450

  Hammond, T G ^a   Pollard, C E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

hERG; Proarrhythmia; QT interval prolongation

Indexed keywords

POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; AMINO ACID SEQUENCE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; IC 50; IN VITRO STUDY; MOLECULAR INTERACTION; NONHUMAN; POTASSIUM CURRENT; PREDICTION; PROTEIN DOMAIN; QT INTERVAL; QT PROLONGATION; RECEPTOR BLOCKING; TORSADE DES POINTES;

ORYCTOLAGUS CUNICULUS;

EID: 24644476159     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.03.022     Document Type: Conference Paper

References (35)

1. C. Antzelevitch, and W. Shimizu Cellular mechanisms underlying the long QT syndrome Curr. Opin. Cardiol. 17 2002 43 51
2. C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A.C. Zygmunt, A. Burashnikov, J.M. Diego, J.M. Fish, J.M. Cordeiro, R.J. Goodrow Jr., F. Scornik, and G. Perez Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent J. Cardiovasc. Pharmacol. Ther. 9 Suppl. 1 2004 S65 S83
3. C. Antzelevitch, L. Belardinelli, A.C. Zygmunt, A. Burashnikov, J.M. Di Diego, J.M. Fish, J.M. Cordeiro, and G. Thomas Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 2004 904 910
4. L. Belardinelli, C. Antzelevitch, and M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol. Sci. 24 2003 619 625
5. R. Bloise, C. Napolitano, and S.G. Priori Romano-Ward and other congenital long QT syndromes Cardiovasc. Drugs Ther. 16 2002 19 23
6. A. Cavalli, E. Poluzzi, F. De Ponti, and M. Recanatini Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers J. Med. Chem. 45 2002 3844 3853
7. C.S. Cheng, D. Alderman, J. Kwash, J. Dessaint, R. Patel, M.K. Lescoe, M.B. Kinrade, and W. Yu A high-throughput HERG potassium channel function assay: an old assay with a new look Drug Dev. Ind. Pharm. 28 2002 177 191
8. S. Ekins, R.B. Kim, B.F. Leake, A.H. Dantzig, E.G. Schuetz, L.B. Lan, K. Yasuda, R.L. Shepard, M.A. Winter, JD. Schuetz, JH. Wikel, and S.A. Wrighton Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein Mol. Pharmacol. 61 2002 964 973
9. L. Fabritz, P. Kirchhof, M.R. Franz, L. Eckardt, G. Monnig, P. Milberg, G. Breithardt, and W. Haverkamp Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia Basic Res. Cardiol. 98 2003 25 32
10. E. Ficker, Y.A. Kuryshev, A.T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B.A. Wible, and A.M. Brown Mechanisms of arsenic-induced prolongation of cardiac repolarization Mol. Pharmacol. 66 2004 33 44
11. K. Finlayson, L. Turnbull, C.T. January, J. Sharkey, and J.S. Kelly [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen Eur. J. Pharmacol. 430 2001 147 148
12. L.M. Hondeghem, and P. Hoffmann Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability J. Cardiovasc. Pharmacol. 41 2003 14 24
13. L.M. Hondeghem, L. Carlsson, and G. Duker Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic Circulation 103 2001 2004 2013
14. L.M. Hondeghem, H.R. Lu, K. van Rossem, and F. De Clerck Detection of proarrhythmia in the female rabbit heart: blinded validation J. Cardiovasc. Electrophysiol. 14 2003 287 294
15. L. Kiss, P.B. Bennett, V.N. Uebele, K.S. Koblan, S.A. Kane, B. Neagle, and K. Schroeder High throughput ion-channel pharmacology: planar-array-based voltage clamp Assay Drug Dev. Technol. 1 2003 127 135
16. Lawrence, C.L., Pollard, C.E., Hammond, T.G., Valentin, J.P., in press. Non-clinical proarrhythmia models: predicting torsades de pointes. J. Pharmacol. Toxicol. Methods.
17. P. Milberg, L. Eckardt, H.J. Bruns, J. Biertz, S. Ramtin, N. Reinsch, D. Fleischer, P. Kirchhof, L. Fabritz, G. Breithardt, and W. Haverkamp Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes J. Pharmacol. Exp. Ther. 303 2002 218 225
18. P. Milberg, S. Ramtin, G. Monnig, N. Osada, K. Wasmer, G. Breithardt, W. Haverkamp, and L. Eckardt Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block J. Cardiovasc. Pharmacol. 44 2004 278 286
19. J.S. Mitcheson, and M.D. Perry Molecular determinants of high-affinity drug binding to HERG channels Curr. Opin. Drug Discovery Dev. 6 2003 667 674
20. R. Netzer, U. Bischoff, and A. Ebneth HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery Curr. Opin. Drug Discovery Dev. 6 2003 462 469
21. R. Pearlstein, R. Vaz, and D. Rampe Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior J. Med. Chem. 46 2003 2017 2022
22. R.A. Pearlstein, R.J. Vaz, J. Kang, X.L. Chen, M. Preobrazhenskaya, A.E. Shchekotikhin, A.M. Korolev, L.N. Lysenkova, O.V. Miroshnikova, J. Hendrix, and D. Rampe Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches Bioorg. Med. Chem. Lett. 13 2003 1829 1835
23. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
24. D.M. Roden, and A.L. George Jr. The cardiac ion channels: relevance to management of arrhythmias Annu. Rev. Med. 47 1996 135 148
25. G. Schram, L. Zhang, K. Derakhchan, J.R. Ehrlich, L. Belardinelli, and S. Nattel Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects Br. J. Pharmacol. 142 2004 1300 1308
26. Y. Song, J.C. Shryock, L. Wu, and L. Belardinelli Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes J. Cardiovasc. Pharmacol. 44 2004 192 199
27. W. Tang, J. Kang, X. Wu, D. Rampe, L. Wang, H. Shen, Z. Li, D. Dunnington, and T. Garyantes Development and evaluation of high throughput functional assay methods for HERG potassium channel J. Biomol. Screening 6 2001 325 331
28. M.B. Thomsen, P.G. Volders, M. Stengl, R.L. Spaatjens, J.D. Beekman, U. Bischoff, M.A. Kall, K. Frederiksen, J. Matz, and M.A. Vos Electrophysiological safety of sertindole in dogs with normal and remodeled hearts J. Pharmacol. Exp. Ther. 307 2003 776 784
29. K. Titier, M. Canal, E. Deridet, A. Abouelfath, S. Gromb, M. Molimard, and N. Moore Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice Toxicol. Appl. Pharmacol. 199 2004 52 60
30. G.N. Tseng I(Kr): the hERG channel J. Mol. Cell. Cardiol. 33 2001 835 849
31. J.I. Vandenberg, B.D. Walker, and T.J. Campbell HERG K+ channels: friend and foe Trends Pharmacol. Sci. 22 2001 240 246
32. R. Webster, D. Leishman, and D. Walker Towards a drug concentration effect relationship for QT prolongation and torsades de pointes Curr. Opin. Drug Discovery Dev. 5 2002 116 126
33. Y.G. Yap, and A.J. Camm Drug induced QT prolongation and torsades de pointes Heart 89 2003 1363 1372
34. M. Zabel, S.H. Hohnloser, S. Behrens, R.L. Woosley, and M.R. Franz Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart J. Cardiovasc. Electrophysiol. 8 1997 1239 1245
35. M. Zabel, M. Malik, K. Hnatkova, V. Papademetriou, A. Pittaras, R.D. Fletcher, and M.R. Franz Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in male US veterans Circulation 105 2002 1066 1070